

Curriculum Vitae

Name in Full	Seong-Hoon Shin , M.D. PhD.	Country	Republic of Korea
Affiliation	Kosin University Gospel Hospital Member, Korean Medical Association Member, Korean Association of Internal Medicine Member, Korean Cancer Association Member, ASCO (American Society of Medical Oncology) Member, MASCC (Multinational Association Of Supportive Care In Cancer)		
Educational Background			
1991-1992	Pre-Medicine	Kosin medical college Busan, Korea	
1993-1997	M.D.	College of Medicine Kosin University Busan, Korea	
1999-2000	Master of Science	Postgraduate School Kosin College of Medicine Busan, Korea	
2007-2014	PhD. (Internal Medicine)	Postgraduate School Inje College of Medicine Busan, Korea	
Professional Career			
1997-1998	Internship	Kosin Medical Center Busan, Korea	
1998-2002	Residency, Internal Medicine	Kosin Medical Center Busan, Korea	
2005-2006	Fellowship in Medical Oncology and Hematology	Kosin Medical Center Busan, Korea	
2007-2012	Assistant Professor	Division of Medical Oncology Department of Internal Medicine Kosin University Gospel Hospital	

2012-2013 M.D. Anderson Cancer Center, University of Texas,
Houston, Texas, USA. Visiting Assistant Professor
2014- Associate Professor
Division of Medical Oncology
Department of Internal Medicine
Kosin University Gospel Hospital
2016-2017 Chief. Division of Medical Oncology

Research Field

1. Kim JW, Kim SH, Kim YJ, Lee KW, Kim KI, Lee JS, Kim CH, Kim JH; Korean Cancer Study Group Geriatric Oncology Working Party. A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7. PLoS One. 2015 Sep 24;10(9)
2. Delgado-Guay MO, Rodriguez-Nunez A, **Shin SH**, Chisholm G, Williams J, Frisbee-Hume S, Bruera E. Characteristics and outcomes of patients with advanced cancer evaluated by a palliative care team at an emergency center. A retrospective study. Support Care Cancer. 2016 May;24(5):2287-95
3. Kim M, Keam B, Kim TM, Kim HG, Kim JS, Lee SS, **Shin SH**, Kim MK, Park KU, Kim DW, Yun HJ, Lee JS, Heo DS. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. Cancer Res Treat. 2016 Jul 28
4. Kim SN, Choi SO, **Shin SH**, Ryu JS, Baik JW Development of a Community-Based Palliative Care Model for Advance Cancer Patients in Public Health Centers in Busan, Korea. Cancer Res Treat. 2016 Oct 18
5. Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, **Shin SH**, Woo IS, Hong S, Kim TY, Kim SY, Nam BH, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Bae SH, Koo DH, Kim KI, Kim JH. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. Br J Cancer. 2018 May;118(9):1169-1175. doi: 10.1038/s41416-018-0037-6. Epub 2018 Mar 26.
6. Huh SY, **Shin SH**, Kim MK, Lee SY, Son KH, Shin HY. Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer. J Clin Neurol. 2018 Jan;14(1):115-117
7. Choi SO, Kim SN, **Shin SH**, Ryu JS, Baik JW, Kim JR, Kim NH Evaluation of Outcomes of the Busan Community-based Palliative Care Project in Korea. Asian Nurs Res (Korean Soc Nurs Sci). 2018 Dec;12(4):286-292.
8. Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, **Shin SH**, Woo IS, Hong S, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, Lee KH, Kim JH Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. Cancer Res Treat. 2019 Jan 2.
9. Kim SH, Kim JW, Hwang IG, Jang JS, Hong S, Kim TY, Baek JY, **Shin SH**, Sun S, Hong DS, Kim HJ, Hong YS, Woo IS, Lee JH, Kim JH. Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. J Geriatr Oncol. 2019 Apr 2